Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.
Request Insights
IN THE NEWSNovember 15, 2021: - Pluristem Therapeutics Inc. the leading biotechnology company, announced the commencement of its multinational Phase III multicenter research on muscle regeneration.
January 28, 2021: PromoCell GmbH to lead a research on immunotherapies through all human primary cells and blood & stem cells, including MHC class I genes HLA-A, -B, and -C.
Global Mesenchymal Stem Cells Market Highlights over 2022 – 2031
The global mesenchymal stem cells market is estimated to grow at a CAGR of ~5% over the forecast period, i.e., 2022 – 2031. Mesenchymal stem cells are multipotent cells that have regenerative properties, and can mature into tissues. The growth of the market can be attributed to the growing demand for treatment of various degenerative and rare diseases, including osteoporosis, cancer, spinal cord injuries, type 1 diabetes, Parkinson's disease, cartilage infection, and ischemic cardiac diseases. The growing prevalence of these ailments is anticipated to be the primary growth driver for the market. According to the data by the World Health Organization (WHO), in 2017 9 million people were suffering with type 1 diabetes. Moreover, a report by the Parkinson's Foundation revealed that around 10 million people worldwide are living with Parkinson’s disease, and 4% of the cases are diagnosed before the age of 50 years. Mesenchymal stem cells or MSCs are extensively used as a regenerative treatment method, which is estimated to boost the market growth. Furthermore, the growing awareness amongst people regarding early diagnosis and treatment of rare diseases, along with growing healthcare expenditure, are projected to influence the market development.
The market is segmented by source into bone marrow, umbilical cord, adipose tissue, molar cells, and others, out of which, the umbilical cord segment is anticipated to hold a substantial share in the global mesenchymal stem cells market over the forecast period. This can be accounted to the growing awareness amongst parents about the high regenerative properties of the umbilical cord cells, along with the increasing trend of storing the cells for the future. On the other hand, the bone marrow segment is also estimated to gain notable growth throughout the forecast period, owing to the rising approach of using bone marrow cells to treat bone or cartilage injuries. CLICK TO DOWNLOAD SAMPLE REPORT
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Mesenchymal Stem Cells Market Regional Synopsis
On the basis of geographical analysis, the global mesenchymal stem cells market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of increasing awareness regarding healthcare amongst people, along with improving healthcare facilities in the region.
The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the increasing adoption of advanced healthcare technologies amongst the developed countries. Moreover, countries, such as, the U.S. and Canada, have high prevalence of osteoporosis and Parkinson’s diseases among other chronic diseases. As per the data by the U.S. Center of Disease Control and Prevention (CDC), 12.6% of the adults aged over 50 years have osteoporosis in femur neck or lumbar spine or both.
The global mesenchymal stem cells market is further classified on the basis of region as follows:
North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Market Segmentation
Our in-depth analysis of the global mesenchymal stem cells market includes the following segments:
By Type
By Sources
By Application
Growth Drivers
Challenges
Top Featured Companies Dominating the Market
FREQUENTLY ASKED QUESTIONS
The growing demand for regenerative treatment, along with growing awareness about stem cells are estimated to boost the market growth.
The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2022 – 2031.
The major players in the market are Merck Group, Genlantis Inc., Celprogen Inc., PromoCell GmbH, Cyagen Biosciences, Cytori Therapeutics Inc., Human Longevity Inc., Thermo Fisher Scientific, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by type, source, application, and by region.
The umbilical cord segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Very high cost of stem cell treatment is estimated to hamper the market growth.
The market in the North America region is estimated to provide more business opportunities for growth over the forecast period owing to the advancement in technology in the healthcare sector.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
